RU165

RU165 is a designation that has been applied to various entities, most notably as a drug candidate and a scientific research project. In the context of pharmaceutical research, RU165 was an experimental drug developed by Roussel Uclaf, a French pharmaceutical company. It was investigated for its potential therapeutic applications, particularly in the realm of endocrinology. Specifically, RU165 was studied for its antiprogestogenic and antiglucocorticoid properties. Research aimed to understand its effects on hormone receptors and its potential as a tool for studying hormone-dependent biological processes.

The development and investigation of RU165 were part of broader scientific efforts to understand and modulate the body's hormonal systems. Studies on RU165 contributed to the scientific understanding of progesterone and glucocorticoid receptor antagonists. While it may not have progressed to widespread clinical use, the research conducted on RU165 provided valuable insights for the pharmaceutical industry and academic research. Its legacy lies in its contribution to the scientific literature and the progression of drug discovery in related fields. The designation RU165, therefore, represents a specific point in the history of pharmaceutical research and development.